Traduction de «authorities and clinical » (Néerlandais → Français) :

De poster kan u hier raadplegen: Belgian health authorities and clinical pharmacy projects (.PDF).
Le poster est mis à votre disposition: Belgian health authorities and clinical pharmacy projects (.PDF)

Belgian health authorities and clinical pharmacy projects (.PDF), FOD Volksgezondheid en het Netwerk van Medisch-farmaceutische comités, H. Robays, L. Willems.
Belgian health authorities and clinical pharmacy projects (.PDF), SPF Santé publique et le Réseau des Comités Médico-pharmaceutiques, H. Robays, L. Willems.

Moreover, as the competent authority, the FAMHP intends to play a catalysing role in the stimulation and conduct of high-quality clinical research (e.g. general clinical research, academic clinical research, paediatric clinical research) in Belgium on an ongoing basis.
Moreover, as the competent authority, the FAMHP intends to play a catalysing role in the stimulation and conduct of high-quality clinical research (e.g. general clinical research, academic clinical research, paediatric clinical research) in Belgium on an ongoing basis.

The Clinical Trial Facilitation Group (CTFG) is a collaborative effort to facilitate and harmonise clinical trials in Europe. Within the CTFG agreements have been made for various competent authorities to voluntarily arrive at a common evaluation for applications for clinical trials whenever this involves multicentre trials with participating centres from different Member States.
The Clinical Trial Facilitation Group (CTFG) is a collaborative effort to facilitate and harmonise clinical trials in Europe. Within the CTFG agreements have been made for various competent authorities to voluntarily arrive at a common evaluation for applications for clinical trials whenever this involves multicentre trials with participating centres from different Member States.

40. White AC Jr, Atmar RL, Wilson J et al: Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities and clinical outcomes.
40. White AC Jr, Atmar RL, Wilson J et al : Effects of requiring prior authorization for selected antimicrobials : expenditures, susceptibilities and clinical outcomes.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.